These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 35804188)
1. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. van der Doelen MJ; Oving IM; Wyndaele DNJ; van Basten JP; Terheggen F; van de Luijtgaarden ACM; Oyen WJG; van Schelven WD; van den Berkmortel F; Mehra N; Janssen MJR; Prins JB; Gerritsen WR; Custers JAE; van Oort IM Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):142-150. PubMed ID: 35804188 [TBL] [Abstract][Full Text] [Related]
2. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. De Vincentis G; Frantellizzi V; Follacchio GA; Farcomeni A; Pani A; Samaritani R; Schinzari G; Santini D; Cortesi E Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13112. PubMed ID: 31148330 [TBL] [Abstract][Full Text] [Related]
3. Baseline quality of life predicts overall survival in patients with mCRPC treated with Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727 [TBL] [Abstract][Full Text] [Related]
4. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273 [TBL] [Abstract][Full Text] [Related]
5. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study. Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555 [TBL] [Abstract][Full Text] [Related]
6. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296 [TBL] [Abstract][Full Text] [Related]
8. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408 [TBL] [Abstract][Full Text] [Related]
11. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557 [TBL] [Abstract][Full Text] [Related]
12. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839 [TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905 [TBL] [Abstract][Full Text] [Related]
15. Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer. Yang H; Kim VS; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen A; Tomlinson G; Alibhai SMH J Geriatr Oncol; 2023 Jan; 14(1):101395. PubMed ID: 36988103 [TBL] [Abstract][Full Text] [Related]
16. Impact of pre-treatment variables on the completion of Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056 [TBL] [Abstract][Full Text] [Related]
17. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM; Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888 [TBL] [Abstract][Full Text] [Related]
18. Review of Palliative Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158 [TBL] [Abstract][Full Text] [Related]
19. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Raimondi A; Sepe P; Claps M; Maccauro M; Aliberti G; Pagani F; Apollonio G; Randon G; Peverelli G; Seregni E; Verzoni E; Procopio G Tumori; 2020 Oct; 106(5):406-412. PubMed ID: 32116138 [TBL] [Abstract][Full Text] [Related]
20. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G Oncology; 2018; 94(3):161-166. PubMed ID: 29241166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]